Pharmaceutical Reform : A Guide to Improving Performance and Equity
This publication, which is based on the unique methodology and tools developed for the World Bank Institute/Harvard School of Public Health Flagship Course on Health System Reform and Sustainable Financing, provides a powerful set of resources to h...
| Main Authors: | , |
|---|---|
| Format: | Publication |
| Language: | English |
| Published: |
World Bank
2012
|
| Subjects: | |
| Online Access: | http://www-wds.worldbank.org/external/default/main?menuPK=64187510&pagePK=64193027&piPK=64187937&theSitePK=523679&menuPK=64187510&searchMenuPK=64187283&siteName=WDS&entityID=000386194_20110928013526 http://hdl.handle.net/10986/2353 |
| id |
okr-10986-2353 |
|---|---|
| recordtype |
oai_dc |
| repository_type |
Digital Repository |
| institution_category |
Foreign Institution |
| institution |
Digital Repositories |
| building |
World Bank Open Knowledge Repository |
| collection |
World Bank |
| language |
English |
| topic |
ABUSE ACCOUNTABILITY ACQUIRED IMMUNODEFICIENCY SYNDROME BIOLOGICALS BRAND BRIBERY BUDGETING CANCER CAPSULES CARDIOVASCULAR DISEASE CENTRAL MEDICAL STORES CHEMISTS CHILD MORTALITY CHRONIC DISEASES CIF CITIZENS CITIZENSHIP CIVIL SOCIETY ORGANIZATIONS CLINICAL TRIALS CLINICS COMMODITIES COMPETITIVE BIDDING COMPETITIVENESS COMPLICATIONS CONSUMER GROUPS CORRUPTION DEATH RATES DECISION MAKING DELIVERY SYSTEMS DEMOCRACY DEVELOPING COUNTRIES DEVELOPMENT GOALS DEVELOPMENT POLICY DIABETES DISABILITY DISCRIMINATION DISSEMINATION DISTRIBUTION SYSTEMS DOMESTIC MANUFACTURERS DONOR FINANCING DOSAGE FORMS DRUG CONTROL DRUG DONATIONS DRUG INDUSTRY DRUG PRICES DRUGS ECONOMIC GROWTH EDUCATION SYSTEMS EMERGING MARKETS ENVIRONMENTAL PROTECTION ESSENTIAL DRUGS ESSENTIAL MEDICINES FAMILIES FAMILY MEMBERS FAVORITISM FIXED COSTS FRAUD FUTURE GROWTH GENERIC DRUGS GLOBAL DEVELOPMENT GLOBAL POLICY GMP GOOD GOVERNANCE GOOD MANUFACTURING PRACTICES GOVERNMENT AGENCIES HEALTH CARE HEALTH CARE ACCESS HEALTH CARE PROVIDERS HEALTH CARE REFORM HEALTH CARE SYSTEM HEALTH CENTERS HEALTH FACILITIES HEALTH INSURANCE HEALTH MANAGEMENT HEALTH OUTCOMES HEALTH POLICIES HEALTH POLICY HEALTH REFORM HEALTH SECTOR HEALTH SERVICES HEALTH SYSTEM HEALTH SYSTEMS HEALTH WORKERS HIGH BLOOD PRESSURE HIV HOME COUNTRIES HOSPITAL HOSPITALS HUMAN DEVELOPMENT HUMAN IMMUNODEFICIENCY VIRUS ILLNESS ILLNESSES IMMUNIZATION IMMUNODEFICIENCY IMPORTED DRUGS INDUSTRIAL DEVELOPMENT INDUSTRIAL PRODUCTION INFORMATION SYSTEMS INTERMEDIARIES INTERNATIONAL AGREEMENTS INTERNATIONAL ORGANIZATIONS INVENTORY INVENTORY MANAGEMENT LABORATORIES LAWS LEGAL STATUS LIFE EXPECTANCY LOCAL ECONOMY LOCAL MANUFACTURERS LOW-INCOME COUNTRIES LOW-INCOME COUNTRY MALARIA MANAGEMENT SYSTEMS MARKET ENTRY MARKETING MEDICAL EDUCATION MEDICAL NEEDS MEDICAL SCHOOL MEDICAL SERVICES MEDICAL SPECIALISTS MEDICAL SUPPLIES MEDICINE MEDICINES MILLENNIUM DEVELOPMENT GOALS MINISTRIES OF HEALTH MINISTRY OF HEALTH MORTALITY NARCOTICS NATIONAL DRUG NATIONAL GOVERNMENT NATIONAL LEGISLATION NURSE NURSES NUTRITION OPERATING COSTS PACKAGING PATIENT PATIENTS PAYMENT TERMS PERSONAL RELATIONSHIPS PHARMACEUTICAL PHARMACEUTICAL COMPANIES PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MARKETING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICIES PHARMACEUTICAL POLICY PHARMACEUTICAL PRICING PHARMACEUTICAL PRICING POLICIES PHARMACEUTICAL PROCUREMENT PHARMACEUTICAL PRODUCTS PHARMACEUTICAL REFORM PHARMACEUTICAL REGULATION PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICAL ¸ MANUFACTURERS PHARMACEUTICALS PHARMACIES PHARMACISTS PHARMACOLOGISTS PHARMACY PHYSICIANS POLICY DECISIONS POLICY FRAMEWORK POLICY GOALS POLICY MAKERS POLITICAL CHANGE POLITICAL DECISION POLITICAL OPPOSITION POLITICAL SUPPORT POOLED PROCUREMENT PRACTITIONERS PRESCRIPTIONS PRICE REGULATION PRIVATE PHARMACIES PROCUREMENT PROGRESS PUBLIC HEALTH PUBLIC HEALTH POLICY PUBLIC POLICY PUBLIC SUPPORT PURCHASING PURCHASING POWER QUALITY ASSURANCE QUALITY CONTROL QUALITY OF CARE QUANTITATIVE DATA RATIONAL USE OF DRUGS REFORM EFFORT REGULATORY AGENCIES REGULATORY AUTHORITIES REGULATORY BARRIERS RESPECT RETAIL RETAIL PHARMACIES RISK FACTORS RURAL AREAS SALES SECURE SUPPLY SERVICE DELIVERY SERVICE PROVIDERS SERVICE QUALITY SOCIAL SECURITY STOCKS SUPPLIER SUPPLIERS SUPPLY CHAIN SUPPLY CHAINS TABLETS TECHNICAL CAPACITY TRADE ISSUES TRANSPORTATION TUBERCULOSIS TURNOVER UNEMPLOYMENT UNEMPLOYMENT RATES UNIVERSAL ACCESS URBAN POPULATION USE OF RESOURCES VACCINES WAREHOUSE WAREHOUSES WHOLESALERS WORKERS WORLD HEALTH ORGANIZATION |
| spellingShingle |
ABUSE ACCOUNTABILITY ACQUIRED IMMUNODEFICIENCY SYNDROME BIOLOGICALS BRAND BRIBERY BUDGETING CANCER CAPSULES CARDIOVASCULAR DISEASE CENTRAL MEDICAL STORES CHEMISTS CHILD MORTALITY CHRONIC DISEASES CIF CITIZENS CITIZENSHIP CIVIL SOCIETY ORGANIZATIONS CLINICAL TRIALS CLINICS COMMODITIES COMPETITIVE BIDDING COMPETITIVENESS COMPLICATIONS CONSUMER GROUPS CORRUPTION DEATH RATES DECISION MAKING DELIVERY SYSTEMS DEMOCRACY DEVELOPING COUNTRIES DEVELOPMENT GOALS DEVELOPMENT POLICY DIABETES DISABILITY DISCRIMINATION DISSEMINATION DISTRIBUTION SYSTEMS DOMESTIC MANUFACTURERS DONOR FINANCING DOSAGE FORMS DRUG CONTROL DRUG DONATIONS DRUG INDUSTRY DRUG PRICES DRUGS ECONOMIC GROWTH EDUCATION SYSTEMS EMERGING MARKETS ENVIRONMENTAL PROTECTION ESSENTIAL DRUGS ESSENTIAL MEDICINES FAMILIES FAMILY MEMBERS FAVORITISM FIXED COSTS FRAUD FUTURE GROWTH GENERIC DRUGS GLOBAL DEVELOPMENT GLOBAL POLICY GMP GOOD GOVERNANCE GOOD MANUFACTURING PRACTICES GOVERNMENT AGENCIES HEALTH CARE HEALTH CARE ACCESS HEALTH CARE PROVIDERS HEALTH CARE REFORM HEALTH CARE SYSTEM HEALTH CENTERS HEALTH FACILITIES HEALTH INSURANCE HEALTH MANAGEMENT HEALTH OUTCOMES HEALTH POLICIES HEALTH POLICY HEALTH REFORM HEALTH SECTOR HEALTH SERVICES HEALTH SYSTEM HEALTH SYSTEMS HEALTH WORKERS HIGH BLOOD PRESSURE HIV HOME COUNTRIES HOSPITAL HOSPITALS HUMAN DEVELOPMENT HUMAN IMMUNODEFICIENCY VIRUS ILLNESS ILLNESSES IMMUNIZATION IMMUNODEFICIENCY IMPORTED DRUGS INDUSTRIAL DEVELOPMENT INDUSTRIAL PRODUCTION INFORMATION SYSTEMS INTERMEDIARIES INTERNATIONAL AGREEMENTS INTERNATIONAL ORGANIZATIONS INVENTORY INVENTORY MANAGEMENT LABORATORIES LAWS LEGAL STATUS LIFE EXPECTANCY LOCAL ECONOMY LOCAL MANUFACTURERS LOW-INCOME COUNTRIES LOW-INCOME COUNTRY MALARIA MANAGEMENT SYSTEMS MARKET ENTRY MARKETING MEDICAL EDUCATION MEDICAL NEEDS MEDICAL SCHOOL MEDICAL SERVICES MEDICAL SPECIALISTS MEDICAL SUPPLIES MEDICINE MEDICINES MILLENNIUM DEVELOPMENT GOALS MINISTRIES OF HEALTH MINISTRY OF HEALTH MORTALITY NARCOTICS NATIONAL DRUG NATIONAL GOVERNMENT NATIONAL LEGISLATION NURSE NURSES NUTRITION OPERATING COSTS PACKAGING PATIENT PATIENTS PAYMENT TERMS PERSONAL RELATIONSHIPS PHARMACEUTICAL PHARMACEUTICAL COMPANIES PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MARKETING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICIES PHARMACEUTICAL POLICY PHARMACEUTICAL PRICING PHARMACEUTICAL PRICING POLICIES PHARMACEUTICAL PROCUREMENT PHARMACEUTICAL PRODUCTS PHARMACEUTICAL REFORM PHARMACEUTICAL REGULATION PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICAL ¸ MANUFACTURERS PHARMACEUTICALS PHARMACIES PHARMACISTS PHARMACOLOGISTS PHARMACY PHYSICIANS POLICY DECISIONS POLICY FRAMEWORK POLICY GOALS POLICY MAKERS POLITICAL CHANGE POLITICAL DECISION POLITICAL OPPOSITION POLITICAL SUPPORT POOLED PROCUREMENT PRACTITIONERS PRESCRIPTIONS PRICE REGULATION PRIVATE PHARMACIES PROCUREMENT PROGRESS PUBLIC HEALTH PUBLIC HEALTH POLICY PUBLIC POLICY PUBLIC SUPPORT PURCHASING PURCHASING POWER QUALITY ASSURANCE QUALITY CONTROL QUALITY OF CARE QUANTITATIVE DATA RATIONAL USE OF DRUGS REFORM EFFORT REGULATORY AGENCIES REGULATORY AUTHORITIES REGULATORY BARRIERS RESPECT RETAIL RETAIL PHARMACIES RISK FACTORS RURAL AREAS SALES SECURE SUPPLY SERVICE DELIVERY SERVICE PROVIDERS SERVICE QUALITY SOCIAL SECURITY STOCKS SUPPLIER SUPPLIERS SUPPLY CHAIN SUPPLY CHAINS TABLETS TECHNICAL CAPACITY TRADE ISSUES TRANSPORTATION TUBERCULOSIS TURNOVER UNEMPLOYMENT UNEMPLOYMENT RATES UNIVERSAL ACCESS URBAN POPULATION USE OF RESOURCES VACCINES WAREHOUSE WAREHOUSES WHOLESALERS WORKERS WORLD HEALTH ORGANIZATION Roberts, Marc J. Reich, Michael R. Pharmaceutical Reform : A Guide to Improving Performance and Equity |
| geographic_facet |
The World Region |
| description |
This publication, which is based on the
unique methodology and tools developed for the World Bank
Institute/Harvard School of Public Health Flagship Course on
Health System Reform and Sustainable Financing, provides a
powerful set of resources to help policy makers better
navigate the complicated process of reforming pharmaceutical
systems. Its problem solving approach complements technical
resources and training curricula available on the discrete
elements of a pharmaceutical sector. The application of the
flagship approach to the pharmaceutical sector is both
useful and timely. Ensuring the availability of medicines
and the effective management of their procurement and
distribution is central to the drive to achieve coverage and
access to basic health care that is both universal and
financially sustainable. Together, the methodology and case
materials contained in this publication provide a rich
resource from which policy makers in developing countries
may draw to guide their efforts to meet these challenges.
This book is designed to help participants gain a better
understanding of all that goes on in the pharmaceutical
sector. As noted above, it uses the flagship framework that
we helped develop over the past decade. The essence of that
approach is not to try to tell policy makers in detail what
they should do. Rather it comprises a set of analytical
tools that are combined into an overall, structured
methodology for developing, adopting, and implementing
reform proposals. The flagship framework also includes a
comprehensive review of reform alternatives and a systematic
review of their strengths and weaknesses in various
situations. Throughout this book the authors have used the
flagship framework to structure our analysis of
pharmaceutical reform, continuously and explicitly applying
its methods and concepts to the pharmaceutical sector. With
a few minor exceptions, all the examples and all of the
reform options come directly from pharmaceutical reform
efforts around the world. The authors have also given
specific attention to issues in pharmaceutical policy
related to reproductive health. |
| format |
Publications & Research :: Publication |
| author |
Roberts, Marc J. Reich, Michael R. |
| author_facet |
Roberts, Marc J. Reich, Michael R. |
| author_sort |
Roberts, Marc J. |
| title |
Pharmaceutical Reform : A Guide to
Improving Performance and Equity |
| title_short |
Pharmaceutical Reform : A Guide to
Improving Performance and Equity |
| title_full |
Pharmaceutical Reform : A Guide to
Improving Performance and Equity |
| title_fullStr |
Pharmaceutical Reform : A Guide to
Improving Performance and Equity |
| title_full_unstemmed |
Pharmaceutical Reform : A Guide to
Improving Performance and Equity |
| title_sort |
pharmaceutical reform : a guide to
improving performance and equity |
| publisher |
World Bank |
| publishDate |
2012 |
| url |
http://www-wds.worldbank.org/external/default/main?menuPK=64187510&pagePK=64193027&piPK=64187937&theSitePK=523679&menuPK=64187510&searchMenuPK=64187283&siteName=WDS&entityID=000386194_20110928013526 http://hdl.handle.net/10986/2353 |
| _version_ |
1764385310281564160 |
| spelling |
okr-10986-23532021-04-23T14:02:01Z Pharmaceutical Reform : A Guide to Improving Performance and Equity Roberts, Marc J. Reich, Michael R. ABUSE ACCOUNTABILITY ACQUIRED IMMUNODEFICIENCY SYNDROME BIOLOGICALS BRAND BRIBERY BUDGETING CANCER CAPSULES CARDIOVASCULAR DISEASE CENTRAL MEDICAL STORES CHEMISTS CHILD MORTALITY CHRONIC DISEASES CIF CITIZENS CITIZENSHIP CIVIL SOCIETY ORGANIZATIONS CLINICAL TRIALS CLINICS COMMODITIES COMPETITIVE BIDDING COMPETITIVENESS COMPLICATIONS CONSUMER GROUPS CORRUPTION DEATH RATES DECISION MAKING DELIVERY SYSTEMS DEMOCRACY DEVELOPING COUNTRIES DEVELOPMENT GOALS DEVELOPMENT POLICY DIABETES DISABILITY DISCRIMINATION DISSEMINATION DISTRIBUTION SYSTEMS DOMESTIC MANUFACTURERS DONOR FINANCING DOSAGE FORMS DRUG CONTROL DRUG DONATIONS DRUG INDUSTRY DRUG PRICES DRUGS ECONOMIC GROWTH EDUCATION SYSTEMS EMERGING MARKETS ENVIRONMENTAL PROTECTION ESSENTIAL DRUGS ESSENTIAL MEDICINES FAMILIES FAMILY MEMBERS FAVORITISM FIXED COSTS FRAUD FUTURE GROWTH GENERIC DRUGS GLOBAL DEVELOPMENT GLOBAL POLICY GMP GOOD GOVERNANCE GOOD MANUFACTURING PRACTICES GOVERNMENT AGENCIES HEALTH CARE HEALTH CARE ACCESS HEALTH CARE PROVIDERS HEALTH CARE REFORM HEALTH CARE SYSTEM HEALTH CENTERS HEALTH FACILITIES HEALTH INSURANCE HEALTH MANAGEMENT HEALTH OUTCOMES HEALTH POLICIES HEALTH POLICY HEALTH REFORM HEALTH SECTOR HEALTH SERVICES HEALTH SYSTEM HEALTH SYSTEMS HEALTH WORKERS HIGH BLOOD PRESSURE HIV HOME COUNTRIES HOSPITAL HOSPITALS HUMAN DEVELOPMENT HUMAN IMMUNODEFICIENCY VIRUS ILLNESS ILLNESSES IMMUNIZATION IMMUNODEFICIENCY IMPORTED DRUGS INDUSTRIAL DEVELOPMENT INDUSTRIAL PRODUCTION INFORMATION SYSTEMS INTERMEDIARIES INTERNATIONAL AGREEMENTS INTERNATIONAL ORGANIZATIONS INVENTORY INVENTORY MANAGEMENT LABORATORIES LAWS LEGAL STATUS LIFE EXPECTANCY LOCAL ECONOMY LOCAL MANUFACTURERS LOW-INCOME COUNTRIES LOW-INCOME COUNTRY MALARIA MANAGEMENT SYSTEMS MARKET ENTRY MARKETING MEDICAL EDUCATION MEDICAL NEEDS MEDICAL SCHOOL MEDICAL SERVICES MEDICAL SPECIALISTS MEDICAL SUPPLIES MEDICINE MEDICINES MILLENNIUM DEVELOPMENT GOALS MINISTRIES OF HEALTH MINISTRY OF HEALTH MORTALITY NARCOTICS NATIONAL DRUG NATIONAL GOVERNMENT NATIONAL LEGISLATION NURSE NURSES NUTRITION OPERATING COSTS PACKAGING PATIENT PATIENTS PAYMENT TERMS PERSONAL RELATIONSHIPS PHARMACEUTICAL PHARMACEUTICAL COMPANIES PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MARKETING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICIES PHARMACEUTICAL POLICY PHARMACEUTICAL PRICING PHARMACEUTICAL PRICING POLICIES PHARMACEUTICAL PROCUREMENT PHARMACEUTICAL PRODUCTS PHARMACEUTICAL REFORM PHARMACEUTICAL REGULATION PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICAL ¸ MANUFACTURERS PHARMACEUTICALS PHARMACIES PHARMACISTS PHARMACOLOGISTS PHARMACY PHYSICIANS POLICY DECISIONS POLICY FRAMEWORK POLICY GOALS POLICY MAKERS POLITICAL CHANGE POLITICAL DECISION POLITICAL OPPOSITION POLITICAL SUPPORT POOLED PROCUREMENT PRACTITIONERS PRESCRIPTIONS PRICE REGULATION PRIVATE PHARMACIES PROCUREMENT PROGRESS PUBLIC HEALTH PUBLIC HEALTH POLICY PUBLIC POLICY PUBLIC SUPPORT PURCHASING PURCHASING POWER QUALITY ASSURANCE QUALITY CONTROL QUALITY OF CARE QUANTITATIVE DATA RATIONAL USE OF DRUGS REFORM EFFORT REGULATORY AGENCIES REGULATORY AUTHORITIES REGULATORY BARRIERS RESPECT RETAIL RETAIL PHARMACIES RISK FACTORS RURAL AREAS SALES SECURE SUPPLY SERVICE DELIVERY SERVICE PROVIDERS SERVICE QUALITY SOCIAL SECURITY STOCKS SUPPLIER SUPPLIERS SUPPLY CHAIN SUPPLY CHAINS TABLETS TECHNICAL CAPACITY TRADE ISSUES TRANSPORTATION TUBERCULOSIS TURNOVER UNEMPLOYMENT UNEMPLOYMENT RATES UNIVERSAL ACCESS URBAN POPULATION USE OF RESOURCES VACCINES WAREHOUSE WAREHOUSES WHOLESALERS WORKERS WORLD HEALTH ORGANIZATION This publication, which is based on the unique methodology and tools developed for the World Bank Institute/Harvard School of Public Health Flagship Course on Health System Reform and Sustainable Financing, provides a powerful set of resources to help policy makers better navigate the complicated process of reforming pharmaceutical systems. Its problem solving approach complements technical resources and training curricula available on the discrete elements of a pharmaceutical sector. The application of the flagship approach to the pharmaceutical sector is both useful and timely. Ensuring the availability of medicines and the effective management of their procurement and distribution is central to the drive to achieve coverage and access to basic health care that is both universal and financially sustainable. Together, the methodology and case materials contained in this publication provide a rich resource from which policy makers in developing countries may draw to guide their efforts to meet these challenges. This book is designed to help participants gain a better understanding of all that goes on in the pharmaceutical sector. As noted above, it uses the flagship framework that we helped develop over the past decade. The essence of that approach is not to try to tell policy makers in detail what they should do. Rather it comprises a set of analytical tools that are combined into an overall, structured methodology for developing, adopting, and implementing reform proposals. The flagship framework also includes a comprehensive review of reform alternatives and a systematic review of their strengths and weaknesses in various situations. Throughout this book the authors have used the flagship framework to structure our analysis of pharmaceutical reform, continuously and explicitly applying its methods and concepts to the pharmaceutical sector. With a few minor exceptions, all the examples and all of the reform options come directly from pharmaceutical reform efforts around the world. The authors have also given specific attention to issues in pharmaceutical policy related to reproductive health. 2012-03-19T09:04:40Z 2012-03-19T09:04:40Z 2011-09-21 http://www-wds.worldbank.org/external/default/main?menuPK=64187510&pagePK=64193027&piPK=64187937&theSitePK=523679&menuPK=64187510&searchMenuPK=64187283&siteName=WDS&entityID=000386194_20110928013526 978-0-8213-8760-3 http://hdl.handle.net/10986/2353 English CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo World Bank World Bank Publications & Research :: Publication Publications & Research :: Publication The World Region |